Cargando…

Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria

BACKGROUND: Accurate response parameters are important for patients with brain metastasis (BM) undergoing clinical trials using immunotherapy, considering poorly defined enhancement and variable responses. This study investigated MRI-based surrogate endpoints for patients with BM receiving immunothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Roh, Yun Hwa, Park, Ji Eun, Kang, Sora, Yoon, Shinkyo, Kim, Sang-We, Kim, Ho Sung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594817/
https://www.ncbi.nlm.nih.gov/pubmed/37875970
http://dx.doi.org/10.1186/s40644-023-00624-0
_version_ 1785124731280687104
author Roh, Yun Hwa
Park, Ji Eun
Kang, Sora
Yoon, Shinkyo
Kim, Sang-We
Kim, Ho Sung
author_facet Roh, Yun Hwa
Park, Ji Eun
Kang, Sora
Yoon, Shinkyo
Kim, Sang-We
Kim, Ho Sung
author_sort Roh, Yun Hwa
collection PubMed
description BACKGROUND: Accurate response parameters are important for patients with brain metastasis (BM) undergoing clinical trials using immunotherapy, considering poorly defined enhancement and variable responses. This study investigated MRI-based surrogate endpoints for patients with BM receiving immunotherapy. METHODS: Sixty-three non-small cell lung cancer patients with BM who received immune checkpoint inhibitors and underwent MRI were included. Tumor diameters were measured using a modification of the RECIST 1.1 (mRECIST), RANO-BM, and iRANO adjusted for BM (iRANO-BM). Tumor volumes were segmented on 3D contrast-enhanced T1-weighted imaging. Differences between the sum of the longest diameter (SLD) or total tumor volume at baseline and the corresponding measurement at time of the best overall response were calculated as “changes in SLDs” (for each set of criteria) and “change in volumetry,” respectively. Overall response rate (ORR), progressive disease (PD) assignment, and progression-free survival (PFS) were compared among the criteria. The prediction of overall survival (OS) was compared between diameter-based and volumetric change using Cox proportional hazards regression analysis. RESULTS: The mRECIST showed higher ORR (30.1% vs. both 17.5%) and PD assignment (34.9% vs. 25.4% [RANO-BM] and 19% [iRANO-BM]). The iRANO-BM had a longer median PFS (13.7 months) than RANO-BM (9.53 months) and mRECIST (7.73 months, P = 0.003). The change in volumetry was a significant predictor of OS (HR = 5.87, 95% CI: 1.46–23.64, P = 0.013). None of the changes in SLDs, as determined by RANO-BM or iRANO-BM, were significant predictors of OS, except for the mRECIST, which exhibited a weak association with OS. CONCLUSION: Quantitative volume measurement may be an accurate surrogate endpoint for OS in patients with BM undergoing immunotherapy, especially considering the challenges of multiplicity and the heterogeneity of sub-centimeter size responses. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40644-023-00624-0.
format Online
Article
Text
id pubmed-10594817
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105948172023-10-25 Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria Roh, Yun Hwa Park, Ji Eun Kang, Sora Yoon, Shinkyo Kim, Sang-We Kim, Ho Sung Cancer Imaging Research Article BACKGROUND: Accurate response parameters are important for patients with brain metastasis (BM) undergoing clinical trials using immunotherapy, considering poorly defined enhancement and variable responses. This study investigated MRI-based surrogate endpoints for patients with BM receiving immunotherapy. METHODS: Sixty-three non-small cell lung cancer patients with BM who received immune checkpoint inhibitors and underwent MRI were included. Tumor diameters were measured using a modification of the RECIST 1.1 (mRECIST), RANO-BM, and iRANO adjusted for BM (iRANO-BM). Tumor volumes were segmented on 3D contrast-enhanced T1-weighted imaging. Differences between the sum of the longest diameter (SLD) or total tumor volume at baseline and the corresponding measurement at time of the best overall response were calculated as “changes in SLDs” (for each set of criteria) and “change in volumetry,” respectively. Overall response rate (ORR), progressive disease (PD) assignment, and progression-free survival (PFS) were compared among the criteria. The prediction of overall survival (OS) was compared between diameter-based and volumetric change using Cox proportional hazards regression analysis. RESULTS: The mRECIST showed higher ORR (30.1% vs. both 17.5%) and PD assignment (34.9% vs. 25.4% [RANO-BM] and 19% [iRANO-BM]). The iRANO-BM had a longer median PFS (13.7 months) than RANO-BM (9.53 months) and mRECIST (7.73 months, P = 0.003). The change in volumetry was a significant predictor of OS (HR = 5.87, 95% CI: 1.46–23.64, P = 0.013). None of the changes in SLDs, as determined by RANO-BM or iRANO-BM, were significant predictors of OS, except for the mRECIST, which exhibited a weak association with OS. CONCLUSION: Quantitative volume measurement may be an accurate surrogate endpoint for OS in patients with BM undergoing immunotherapy, especially considering the challenges of multiplicity and the heterogeneity of sub-centimeter size responses. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40644-023-00624-0. BioMed Central 2023-10-24 /pmc/articles/PMC10594817/ /pubmed/37875970 http://dx.doi.org/10.1186/s40644-023-00624-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Roh, Yun Hwa
Park, Ji Eun
Kang, Sora
Yoon, Shinkyo
Kim, Sang-We
Kim, Ho Sung
Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria
title Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria
title_full Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria
title_fullStr Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria
title_full_unstemmed Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria
title_short Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria
title_sort prognostic value of mri volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594817/
https://www.ncbi.nlm.nih.gov/pubmed/37875970
http://dx.doi.org/10.1186/s40644-023-00624-0
work_keys_str_mv AT rohyunhwa prognosticvalueofmrivolumetricparametersinnonsmallcelllungcancerpatientsafterimmunecheckpointinhibitortherapycomparisonwithresponseassessmentcriteria
AT parkjieun prognosticvalueofmrivolumetricparametersinnonsmallcelllungcancerpatientsafterimmunecheckpointinhibitortherapycomparisonwithresponseassessmentcriteria
AT kangsora prognosticvalueofmrivolumetricparametersinnonsmallcelllungcancerpatientsafterimmunecheckpointinhibitortherapycomparisonwithresponseassessmentcriteria
AT yoonshinkyo prognosticvalueofmrivolumetricparametersinnonsmallcelllungcancerpatientsafterimmunecheckpointinhibitortherapycomparisonwithresponseassessmentcriteria
AT kimsangwe prognosticvalueofmrivolumetricparametersinnonsmallcelllungcancerpatientsafterimmunecheckpointinhibitortherapycomparisonwithresponseassessmentcriteria
AT kimhosung prognosticvalueofmrivolumetricparametersinnonsmallcelllungcancerpatientsafterimmunecheckpointinhibitortherapycomparisonwithresponseassessmentcriteria